Head-to-head evidence
Mitiglinide vs repaglinide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SUR1 (short-acting) · full Type 2 Diabetes pipeline
Mitiglinide · Glufast
Developed by Kissei Pharmaceutical
NCT00519142 · Phase 3 · completed
The study randomly assigned 367 participants to quadruple-blinded mitiglinide-plus-metformin or metformin-plus-placebo groups, with a third mitiglinide dosing group. Its primary measure was the change in HbA1c after 24 weeks, a laboratory surrogate endpoint, and no results are available to show whether the comparison favored mitiglinide.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
repaglinide · Prandin / NovoNorm
Marketed by Novo Nordisk
NCT00399711 · Phase 3 · completed
The study was randomized and included an active comparator, with 560 participants, but it was open-label rather than blinded. Its primary endpoint was HbA1c, a surrogate measure, and no primary outcome results are available, so whether the treatment comparison was favorable cannot be assessed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mitiglinide's landscape · repaglinide's landscape